Cargando…

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Ryota, Morimoto, Yukina, Sato, Mizuto, Hikichi, Tetsuro, Yoshida, Kazunari, Toda, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://www.ncbi.nlm.nih.gov/pubmed/32887369
http://dx.doi.org/10.3390/vaccines8030498
_version_ 1783595827755745280
author Tamura, Ryota
Morimoto, Yukina
Sato, Mizuto
Hikichi, Tetsuro
Yoshida, Kazunari
Toda, Masahiro
author_facet Tamura, Ryota
Morimoto, Yukina
Sato, Mizuto
Hikichi, Tetsuro
Yoshida, Kazunari
Toda, Masahiro
author_sort Tamura, Ryota
collection PubMed
description Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas.
format Online
Article
Text
id pubmed-7564945
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75649452020-10-26 A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma Tamura, Ryota Morimoto, Yukina Sato, Mizuto Hikichi, Tetsuro Yoshida, Kazunari Toda, Masahiro Vaccines (Basel) Communication Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was more effective for advanced solid cancers, including melanoma and renal cell carcinoma. However, previous clinical trials demonstrated a high adverse event rate. Additionally, no studies previously assessed treatment efficacy and safety using both VEGF-A and VEGFR-targeted agents for malignant gliomas. We had conducted clinical trials investigating VEGFRs peptide vaccination in patients with malignant gliomas, in which the treatment exhibited safety and yielded therapeutic effects in some patients. The combined use of Bev and VEGFRs vaccination may enhance the anti-tumor effect in malignant gliomas. In this pilot study, the adverse event profile in patients treated with Bev after the vaccination was investigated to establish this treatment strategy, in comparison to those treated with Bev collected from the published data or treated with the vaccination alone. In our previous clinical studies on patients with malignant gliomas, Bev was administered to 13 patients after VEGFRs vaccinations. One patient had a Grade 4 pulmonary embolism. Two patients had Grade 2 cerebral infarctions. There were no significant differences in the adverse event rates among patients treated with Bev, with the vaccination, or with Bev after the vaccination. Although careful observation is imperative for patients after this combination treatment strategy, VEGFRs-targeted vaccination may coexist with Bev for malignant gliomas. MDPI 2020-09-02 /pmc/articles/PMC7564945/ /pubmed/32887369 http://dx.doi.org/10.3390/vaccines8030498 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Tamura, Ryota
Morimoto, Yukina
Sato, Mizuto
Hikichi, Tetsuro
Yoshida, Kazunari
Toda, Masahiro
A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title_full A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title_fullStr A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title_full_unstemmed A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title_short A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma
title_sort pilot study of the adverse events caused by the combined use of bevacizumab and vascular endothelial growth factor receptor-targeted vaccination for patients with a malignant glioma
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564945/
https://www.ncbi.nlm.nih.gov/pubmed/32887369
http://dx.doi.org/10.3390/vaccines8030498
work_keys_str_mv AT tamuraryota apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT morimotoyukina apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT satomizuto apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT hikichitetsuro apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT yoshidakazunari apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT todamasahiro apilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT tamuraryota pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT morimotoyukina pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT satomizuto pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT hikichitetsuro pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT yoshidakazunari pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma
AT todamasahiro pilotstudyoftheadverseeventscausedbythecombineduseofbevacizumabandvascularendothelialgrowthfactorreceptortargetedvaccinationforpatientswithamalignantglioma